转译如下： Chios Mastiha essential oil（CMO）是从乳香树脂提取的一种天然产品，具有抗氧化、抗微生物、抗溃疡、抗肿瘤和降低胆固醇的能力，这些能力已经在体外验证，并且其降血脂的作用也已在动物研究中得到确认。然而，目前文献中关于CMO在人体中降血脂作用的随机安慰剂对照临床研究尚未发表。因此，设计了一项前瞻性、随机、安慰剂对照的研究，以研究CMO胶囊对总胆固醇升高的健康志愿者的降血脂作用。共筛选了192名健康志愿者，其中160名总胆固醇> 200 mg/dl 的患者参与了本研究。这些患者以2：1的比例随机接受CMO胶囊（每粒200毫克乳香油）和安慰剂进行8周治疗。共有113名患者接受了CMO治疗，47名患者随机分配到安慰剂组，在研究期间全部完成了随访。在CMO给药8周后，CMO组的总胆固醇和LDL胆固醇明显低于安慰剂组，分别为215.2±27.5与237.0±27.9 mg/dl（p<0.001），以及135.0±26.1与153.0±23.3 mg/dl（p<0.001）。没有报道任何胃肠道不良事件、肝脏或肾脏毒性。此外，在CMO组中，总胆固醇显著下降了20.6 mg/dl（9％），LDL下降了18.1 mg/dl（12％），甘油三酯下降了21.8 mg/dl（15％），葡萄糖下降了4.6 mg/dl（5％），高密度脂蛋白增加了2.4 mg/dl（5％），与基线值相比。MASTIHA-OIL研究显示，CMO在8周治疗后对健康志愿者的总胆固醇和LDL胆固醇有着显著的降低作用，并且具有良好的安全性。版权所有© 2023 Hellenic Society of Cardiology. 由Elsevier B.V.出版，保留所有权利。

Chios Mastiha essential oil (CMO) is a natural product extracted from the resin of Mastiha, possessing antioxidant, anti-microbial, anti-ulcer, anti-neoplasmatic and cholesterol lowering capabilities in vitro, and its hypolipidemic effect was confirmed in animal studies. Yet, there are no randomized, placebo-controlled clinical studies in the literature regarding CMO's hypolipidemic effects in humans. A prospective, randomized, placebo-controlled study was designed to study the hypolipidemic effect of CMO capsules on healthy volunteers with elevated cholesterol.192 healthy volunteers were screened and 160 of them with total cholesterol> 200 mg/dl participated in the study. They were randomized with a 2:1 ratio of receiving CMO capsules (200 mg mastiha-oil/capsule) and placebo for 8 weeks respectively. 113 patients received CMO and 47 were randomized in the control group, and all of them completed the follow-up period.After 8 weeks of CMO administration, total and LDL cholesterol were significantly lower in the CMO compared to the placebo group 215.2±27.5 vs 237.0±27.9 mg/dl (p<0.001) and 135.0±26.1 vs 153.0±23.3 mg/dl (p<0.001) respectively. No gastrointestinal adverse events, liver or renal toxicity were reported. Additionally, in the CMO group total cholesterol was significantly decreased by 20.6 mg/dl (9%) and LDL by 18.1 mg/dl (12%), triglycerides by 21.8 mg/dl (15%) and glucose by 4.6 mg/dl (5%) and HDL was increased by 2.4 mg/dl (5%), compared to their baseline values.MASTIHA-OIL study showed the efficacy and safety of CMO in reduction of Total and LDL-cholesterol after 8 weeks of administration in healthy volunteers with elevated cholesterol levels.Copyright © 2023 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.